Comparison of American and European (Czech) guidelines for diagnosis and treatment of chronic heart failure

Czech version

Authors: Jindřich Špinar ¹; Lenka Špinarová ²; Jiří Vítovec ²; Ondřej Ludka ¹
Authors‘ workplace: Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC ¹; I. interní kardio-angiologická klinika LF MU a FN u sv. Anny Brno, přednostka prof. MUDr. Lenka Špinarová, CSc., FESC ²
Published in: Vnitř Lék 2014; 60(4): 366-374
Category: 60th Birthday - prof. MUDr. Petr Widimský, DrSc., FESC, FACC

Overview

The new Czech and European recommendations for diagnosis and treatment of heart failure were published in 2012. The American guidelines ACCF/AHA were published in 2013. Main difference between them is presentation of acute and chronic heart failure in the European guidelines while the American and the Czech guidelines include only chronic heart failure. The American recommendations distinguish heart failure with reduced ejection fraction and with remained ejection fraction. In the beginning, the American guidelines introduce A-D classification which doesn´t figure in the European neither Czech guidelines. Class A patients are ill with risk factors, but without heart failure. In contrast, class D patients are decompensated with symptoms in the rest. Epidemiologic data shows interesting results with prevalence about 0.2% in 60–69 years old subjects and 80% in subjects older than 85 years. 5 year mortality is 50%. The American guidelines start to treat class A which is in fact prevention and treatment of risk factors. There is mentioned inevitably treatment of hypertension, both systolic and diastolic which decrease risk of heart failure up to 50%. There is almost no difference in pharmacotherapy. Noteworthy, the American guidelines introduce also ACE inhibitors - fosinopril and quinapril, on the other hand beta-blockers don´t involve nebivolol. Wide range of diuretics are mentioned, some of them aren´t registered in the Czech Republic. European and Czech guidelines involve ivabradin. Neither nesiritid nor levosimendan for inpatients aren´t involved. There is briefly mentioned surgery and cardiac mechanical support, moreover there are references for guidelines for heart transplantation.

Key words:
diagnosis – guidelines – heart failure – treatment

Sources

1. Hradec J, Vítovec J, Špinar J. Summary of the ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Prepared by the Czech Society of cardiology. Cor et Vasa 2013; 55(1): 33–48.

2. Lewine GN, Steinke EE, Bakaeen FG et al. Sexual activity and cardiovascular disease. Circulation 2012; 125(8): 1058–1072.

3. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33(14): 1787–1847.

4. Paulus WJ, Tschope C, Sanderson JE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28(20): 2539–2550.

5. Steinke EE, Jaarsma T, Baunaton SA et al. Sexual Counselling for Individuals with Cardiovascular Disease and Their Partners. Eur Heart J 2013; 34(41):3217–3235.

6. Špinar J, Vítovec J, Hradec J et al. Czech Society of Cardiology guidelines for the diagnosis and treatment of chronic heart failure 2011. Cor et Vasa 2012; 54(3–4): e114-e134.

7. Špinar J, Vítovec J, Hradec J et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání – ČKS 2011. Vnitř Lék 2012; 58(Suppl 1): S4-S40.

8. Špinar J, Vítovec J, Hradec J et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání – ČKS 2011. Cor et Vasa 2012; 54(3–4): 161–182.

9. Špinar J, Vítovec J, Hradec J Co je nového v evropských doporučeních pro diagnostiku a léčbu srdečního selhání. Kardiologická revue 2012; 14(3): 211–212.

10. Špinar J, Vítovec J: Liší se ESC a ČKS doporučení pro diagnostiku a léčbu srdečního selhání? Kardiologická revue 2013; 15(2): 99–103.

11. Špinar J, Vítovec J, Hradec J et al. Srovnání doporučení pro diagnostiku a léčbu chronického srdečního selhání. Cor et vasa 2013; 55(3): 307–313.

12. Špinarová L, Špinar J, Vítovec J. Novinky v léčbě chronického srdečního selhání – guidelines ČKS – srovnání s minulými doporučeními. Remedia 2012; 22(2): 127–131.

13. Yanci CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the Management of Heart failure. JACC 2013; 62(16): e147-e239. Dostupné z DOI: <http://doi: 10.1016/j.jacc.2013.05.019>.